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HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION IN 61 PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: A
SINGLE CENTRE EXPERIENCE
Schonland, S.O.1, Dengler, J.B.1, Bochtler, T.1, Goldschmidt, H.1,
Ho, A.D.1, Hegenbart, U.1 1Univ. of Heidelberg, Med. Department,
Div. of Hematology/Amyloidosis Clinic, Heidelberg, Germany.
Introduction:High-dose chemotherapy (HDC) with autologous
hematopoietic stem cell transplantation (ASCT) is currently the
treatment which induces the highest rates of remission in patients
(pts) with light chain amyloidosis (AL). Due to impaired organ
function in these pts a high treatment-related mortality (TRM) up
to 40% has been published. A high TRM was also noted in a
French multicenter phase III study which compared melphalan /
dexamethasone chemotherapy with HD melphalan. As a conse-
quence no advantage of HDC could be observed in this trial so far
(ASH 2005).
Methods: We have retrospectively analyzed all pts with AL who
received HDC (HD melphalan median 200 mg/m2, range 70-200
in 60 pts and HD-BEAM in 1pt) and ASCT in our centre from
1998 until 2006.
Results: We report on 61 patients (median age 57 years, range
35-69; n7 with multiple myeloma stage I and 1 pt with Walden-
stroms disease) treated with HDC and ASCT in our institution
with a follow up of more than 3 months. Exclusion criteria were
age 70 years, symptomatic heart involvement  NYHA stage II
and WHO performance status 2. The median number of in-
volved organs was 2 (1-5). 5 pts had end stage renal failure at time
of transplant. The median follow-up is 23 months (range, 9 days -
100 months). Complete hematological remission was obtained in
26 out of 54 (48%) and organ response in 22 out of 56 evaluable
patients (39%). In further 31 patients organ function has stabilized
(55%). 48 out of 61 pts are alive (79%), 2 pts died of TRM (3%).
Estimated overall survival at 2 and 4 years is 80% and 66%,
respectively. Hematological relapse or progression occurred in 10
patients (19%) at a median of 27 months. There was a signiﬁcant
difference regarding OS between pts in CR vs. non-CR (p0.001).
Organ progression was noted only in 5 pts with CR and in 15 pts
not reaching CR and occurred later in CR pts (P0.001).
Discussion: HDC is in our view currently the treatment of
choice for pts who are highly selected to be eligible for this
treatment. Here we conﬁrm that high overall response and survival
rates can be achieved with a low TRM in a single institution with
a large experience in AL amyloidosis. The main goal remains
achievement of a CR as organ progression can be prevented in
these pts. Further therapeutic strategies have to focus on non-CR
pts using new drugs effective in the treatment of multiple my-
eloma.
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IMPLICATIONS OF BODY WEIGHT CALCULATIONS FOR AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
Simpson, L.1, Wolfe, R.C.1, Gastineau, D.A.1, Hogan, W.J.1,
Kumar, S.1 1Mayo Clinic, Rochester, MN.
Background: BMI varies greatly among autologous stem cell
transplantation (SCT) recipients. Stem cell collection targets are
usually determined using actual body weight (ABW). Conditioning
chemotherapy doses usually use corrected ideal body weight
(IBW). Since stemcells home to bone marrow, the IBW being
based on the height may better indicate stemcell numbers required
than ABW. Since chemotherapy doses are calculated based on
corrected IBW, and the volume of distribution is higher in obese
patients, these patients may have decreased drug exposure and
higher progression risk.
Methods: Retrospective, single institution evaluation of engraft-
ment kinetics and outcomes of 306 SCTs done between 1998 and
2001 was performed. SCT reasons were myeloma (46%), NHL
(34%), HD (6%) and AL amyloidosis (14%). The stem cell doses
were calculated based on ABW and IBW and correlated with time
to WBC and platelet engraftment. We also evaluated the effect of
BMI on the PFS after SCT using various cutoffs.
Results: The mean (range) of ABW, IBW and BMI were 46.6 kg
to 189 Kg; 45.5 kg to 94 kg; and 17.5 to 55.8 respectively. Using
logistic regression, we estimated the CD34 cell dose by ABW and
IBW that best predicts platelet engraftment (50,000) by day 21
post transplant. The coefﬁcients for both doses were similar (Ideal
0.391; Actual 0.361).Using ROC analysis; we determined the stem
cell dose cutoff that best predicted for failure to engraft neutrophils
by 21 days post transplantation, median CD34 dose by ABW of 3.6
million/Kg and by IBW of 4.2 million/Kg. Similarly, for failure to
engraft platelets by day 30 the cutoffs were 2.89 million/Kg by
ABW and 3.77 million/kg by IBW. Among the individuals with
ABW more than 25% of IBW(n122, 40%), we calculated the
optimal total CD34 dose required and compared to the actual dose
infused using both cutoffs (286 million vs. 446 million, P  0.001
using ANC cutoff and 251 million vs. 446 million using the platelet
cutoff, P 0.001). The PFS and OS post transplant was similar for
patients with BMI over 30 kg/m2 compared to those below this
cutoff. There was no difference when patients with myeloma or
lymphoma were studied separately.
Conclusion: This study conﬁrms prior studies that IBW deter-
mined stem cell dose is comparable to that by ABW. In patients
signiﬁcantly above IBW, it is reasonable to use a target based on
IBW which will allow for collection of less CD34 cells. In SCT
using corrected IBW does not compromise outcomes.
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POOR OUTCOME OF AUTOLOGOUS-BONE MARROW TRANSPLANT
(AUTO-BMT) FOLLOWING FAILED PERIPHERAL BLOOD STEM CELL
(PBSC) MOBILIZATION
Strickland, S.A.1, Chen, H.2, Hunt, C.1, Chinratanalab, W.1,
Engelhardt, B.1, Goodman, S.A.1, Greer, J.P.1, Kassim, A.A.1,
Morgan, D.S.1, Ruffner, K.L.1, Schuening, F.G.1, Jagasia, M.H.1
1Vanderbilt University Medical Center, Department of Medicine, Divi-
sion of Hematology/Oncology, Nashville, TN; 2Vanderbilt University
Medical Center, Department of Biostatistics, Nashville, TN.
BACKGROUND: Auto-PBSC transplant has replaced auto-
BMT. 10-30% of patients (pts) fail to mobilize adequate PBSCs.
Auto-BMT is typically considered in these pts. The results of such
an approach are not well studied.
METHODS: Consecutive pts undergoing high-dose chemother-
apy (HDC) and auto-BMT after failed PBSC mobilization were
evaluated. Nucleated cell (NC) dose, CD34 cell dose, time to
neutrophil (ANC) and platelet (Plt) engraftment were reviewed.
Overall survival (OS) and progression free survival (PFS) were
evaluated.
RESULTS: 22 pts failed to mobilize PBSCs and underwent
marrow harvest followed by HDC and auto-BMT from 2001 to
2006. 3 and 19 pts failed G-CSF and cyclophosphamide/G-CSF
mobilization. The median age was 56 yrs (range, 9-69). Diagnoses
included Non-Hodgkin lymphoma (14,64%), Hodgkin lymphoma
(4,18%), and acute myeloid leukemia (3,14%). The median num-
ber of salvage regimens before attempted PBSC mobilization was
1 (range, 0-4). The median NC and CD34 cell doses of the
marrow infused were 3.7108/kg (range, 1.4-6.8) and 1.0106/kg
(range, 0.3-3.0). All pts achieved ANC engraftment with G-CSF
support at a median of 20.5 days (range, 13-43). 55% (12/22) of the
pts achieved Plt engraftment at a median of 46.5 days (range,
23-92). The NC and CD34 cell dose did not differ signiﬁcantly
in patients with ANC engraftment (20 days or 20 days), Plt
engraftment (45 days or 45 days) or number of salvage regimens
( 1 or 1). There was no correlation between NC dose or
CD34cell dose and time to either ANC engraftment (NC, rho-
0.05, P0.8; CD34, rho-0.2, P0.4) or Plt engraftment
(NC,rho0.6, P0.9; CD34, rho- 0.2, P0.4).Median follow up
was 322 days (range, 53 to 1700). 59% (13/22) patients have
relapsed at a median of 155 days (range, 13-882). Median overall
survival (OS) and median PFS were 1140 and 509 days (95% CI,
368 to 649). Overall mortality was 36% (8/22). Causes of death
were progressive disease (6/8,75%) and treatment related mortality
(2/8,25%). 9/22 (41%) pts are alive without post-transplant relapse
(PTR) at a median follow-up time of 276 (range, 53 to 649). 6 of
these 9 pts continue to have Plt counts 100109/L.
CONCLUSIONS: The relapse rate after auto-BMT in pts who
Poster Session I40
have failed PBSC mobilization is high. Auto-BMT should not be
routinely recommended to pts who have failed PBSC mobilization.
Alternative strategies, including reduced intensity or non-myeloa-
blative allogeneic transplants should be considered in this patient
group.
GRAFT PROCESSING
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AN AUDITED RETROSPECTIVE ANALYSIS OF CORD BLOOD TRANS-
PLANTATION (CBT) OF 230 PATIENTS USING PLASMA DEPLETED
CORD BLOOD UNITS (PD CB)
Chow, R.1,2,3, Wang, B.1, Wu, T.1, Chow, T.1, Gjertson, D.4, Petz, L.1
1StemCyte International Cord Blood Center, Arcadia, CA; 2StemCyte
Taiwan National Cord Blood Center, Linkou, Taiwan; 3StemCyte Re-
search Institute, Arcadia, CA; 4UCLA School of Public Health & UCLA
School of Medicine, Los Angeles, CA.
Limited cell dose has hampered widespread use of CBT. The red
cell depletion (RD) techniques that are widely used incur signiﬁ-
cant nucleated cell loss after processing; therefore, to minimize cell
loss and still reduce volume during processing, a technique was
devised to deplete plasma (PD) but not red blood cells. An updated
retrospective audited analysis of 230 consecutive patients with
engraftment and/or survival data from 81 transplant centers over 5
continents up to September 2006 was performed. The data was
audited in three ways: (1) by CIBMTR using on-site audits for
40% of the PD CBT with available outcome data, (2) by NMDP
for PD CBT that it faciliates, (3) and by the transplant center
working with the cord blood bank. Patient characteristics: median
age 7.9 yo, range 0.3-63, 66 16 yo (29%); median weight 27 kg,
range 4.8-137, 70,50kg (31%); male 59%; median # HLA ABDR
matches 4.0; median pre-freeze TNC dose 5.6  107/kg (n230);
transplant center reported median post-thaw TNC dose 3.9 
107/kg (n219); median pre-freeze CD34 dose 1.8  105/kg;
malignant indications 69%; transplants outside U.S. 37%; double
cord transplant 25%; and non-myeloablative 19%. Of the malig-
nant cases, 40 (26%) had standard risks, 91 (59%) had advanced
risks, and 24 (15%) with unknown status. For all engrafted pa-
tients, the median time to engraftment for ANC 500, platelet 20K
and 50K were 22 days (range 6-69), 48 days (range 12-186), and 62
days (range 21-374) respectively. Kaplan-Meier estimates of en-
graftment of ANC500, platelet 20K and 50K engraftment were
892% (n215), 784% (n196) and 754% (n195) respec-
tively. The incidence of grade III-IV acute GVHD and extensive
chronic GVHD were 13% and 12% respectively. One-year relapse
rate was 254% for all patients (n223), and TRM was 193%
and 293% (n228) at 100 days and 1 year. With a median
follow-up of 258 days (range 2-1741 days) for the surviving pa-
tients, the Kaplan-Meier estimates of 1-year OS (n228) and DFS
(n223) are 583% and 563% respectively. To our knowledge,
this is one of few studies originated by cord blood banks that was
extensively audited by external data and transplant registries. Other
unique aspects were the very high mean and median cell dose as
well as the minority and international focus of the patients. These
results conﬁrm our earlier ﬁndings and demonstrate that CBT
using PD CB can achieve outstanding engraftment and survival.
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A PILOT STUDY CD34 SELECTED HAPLOIDENTICAL TRANSPLANT US-
ING A CHEMOTHERAPY ONLY PREPARATIVE REGIMEN AND INTENSIVE
ANTIBIOTIC PROPHYLAXIS FOR TREATMENT OF ADVANCED LEUKEMIA
Gajewski, J.L.1, McMannis, J.D.2, Shpall, E.J.2, Donato, M.L.3,
Champlin, R.E.2 1Temple University/Fox Chase-Temple BMT Pro-
gram, Philadelphia, PA; 2University of Texas/M.D. Anderson Cancer
Center, Houston, TX; 3Hackensack University, Hackensack, NJ.
We present preliminary data of haploidentical transplant for 13
patients (pts) with acute leukemia using a chemotherapy-only pre-
parative regimen of Melphalan 140 mg/m2 on day –8; Thiotepa 10
mg/kg on day –7; Fludarabine 40 mg/m2 on days –6, -5, -4, -3; 1.5
mg/kg of rabbit ATG/day days –6, -5, -4, -3.aˆ device as a means of
T-cell depletion. All products had 1  104 CD3 T-cells/kg
recipient body weight and needed a minimum of 5  106 CD34
cells/kg but preferably 1  107 CD34 cells/kg recipient body
weight. Age ranged 23-50 years/median 37 years, four patients
were in advanced remission and nine were in refractory relapse.
Patients received intensive PCP prophylaxis with sulfamethox-
azole-trimethoprim and pentamidine prior to transplant and dur-
ing pancytopenia; CMV prophylaxis with valganciclovir during the
BMT prep and foscarnet® while pancytopenic; and with liposomal
amphotericin or cancidas for fungal prophylaxis.
Two patients had primary graft failure-one survived disease free
and one relapsed. One patient died of multiple organ failure prior
to engraftment. Median time to engraftment was 15 days (range,
9-26) to 500 neutrophils and 14 days to platelets 20,000 (range,
13-25).
Seven patients died of relapse at a median of 10 months (range
2-13 months), and one patient died of a viral infection. Two of 10
patients who engrafted developed grade one acute graft-versus-
host (GVHD) and four patients had chronic GVHD (3 limited, 1
extensive). Four patients survive beyond 2 years, without recurrent
disease.
This report for haploidentical transplant demonstrates that a
chemotherapy only preparative regimen can achieve a high rate of
engraftment. Infectious complications were minimal with aggres-
sive prophylaxis. Long-term remission are achievable with little
risk of severe GVHD with t-cell depletion with use of CliniMACSaˆ
in haploidentical stem cell transplant.
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COMBINED BONE MARROW AND PBPC AUTOGRAFTS FOR TRANSPLAN-
TATION OF PATIENTS WITH POOR MOBILIZATION
Sinitsyn, Y.1, Grosskreutz, C.1, Osman, K.1, Scigliano, E.1, Isola, L.1
1Mount Sinai Medical Center, New York, NY.
Background: Autologous BMT has been abandoned in favor of
PBSC collected after G-CSF with or without chemotherapy.
PBPC autografts with low CD34 cell content provide late neu-
trophil and inadequate platelet and red cell reconstitution. Repeat
mobilization and bone marrow harvest are possible ways to cir-
cumvent this problem. No studies address minimum cell contents
for combined PBPC/BM grafts and transplant outcomes using
combined grafts in the context of previous inadequate PBSC col-
lection. Methods: Retrospective analysis of 19 autologous trans-
plants performed with a combined PBPC/BM graft for poor initial
PBPC collection. Mobilization was ﬁlgrastim 10 g/kg/day with-
out chemotherapy x 5 days or after CY, ICE or RICE to peripheral
CD34 count  10/L and until completion of collection. A
standard BM harvest (max 20 mL/kg) was done if collection con-
tained  2.5  106 CD34 / kg. Results: Patients median age was
55 (19-74). Diagnoses: MM (7), NHL (7), HL (4) and AML (1).
Cell contents of the combined grafts were (CD34 / kg x 106
median  standard deviation (range)) for BM 1.1 0.6 (0.3-2.7)
PBPC 1.2  0.7 (0.04-2.8) Infused: 2.2  1.1 (1.4-4.7). Eight
combined grafts contained  2.0  106 CD34 / kg (1.3-1.8).
Engraftment in days as median (range) was: ANC500: 11 (9-39) Plt
20,000: 25 (15-59) RBC independence: 28 (0-58). Six patients died
of progressive disease (58-293 days post-ASCT). One patient died
of infection day 141 and one of MI day 11. All patients maintained
an ANC 1,000 without growth factor support beyond day 19 but
one who required intermittent growth factor support until day 39.
One patient experienced delayed graft failure (platelets  10,000)
on day 90 at concomitantly with acute cholecystitis. The CD34 /
kg content of the PBPC collection alone did not predict that of the
BM harvest but it correlated with time to ANC500 (r  -0.46 p 
0.046) and time to Plt 20,000 (r  -0.54 p  0.037). Neither the
BM nor the total infused CD34 / kg content or the BM TNC/kg
content correlated with engraftment or outcomes. In particular,
patients above or below 2.0  106 CD34/kg had similar kinetics
of engraftment and overall mortality. Conclusions: BM harvest
after failed PBPC collection is a reliable option to obtain an
adequate combined autograft. Combined BM/PBSC grafts can
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